<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940816-2-00071</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  There is no deadline by which license applications must be received. CRADA proposals must be received on or before November 14, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Child Health and Human Development; Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Use of Antiflammins </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, Public Health Service, DHHS.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The National Institutes of Health is seeking licensees and/or CRADA partners for the further development and commercialization of its patent portfolio for antiflammins. The inventions claimed in the following patent applications are available for either exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under one or more CRADAs in several clinically important applications as described below in the Supplementary Information: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=25 g=1 f=1 --> Anti-Inflammatory Agents, Mukherjee, A. B. (NICHD), Filed 19 Nov 1987 Serial No. 07/122,379, U.S. Patent No. 5,266,562 issued 30 Nov 1993 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Method of Treating Ocular Inflammatory Diseases Using Antiflammins, Chan, C. C. (NEI), Filed 7 Jun 1993, Serial No. 08/073,380 <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> To speed the research, development and commercialization of this new class of drugs, the National Institutes of Health is seeking one or more license agreements and/or CRADAs with pharmaceutical or biotechnology companies in accordance with the regulations governing the transfer of Government-developed agents. Any proposal to use antiflammins in the treatment of inflammatory disease processes will be considered.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SUMMARY> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  CRADA proposals and questions about this opportunity should be addressed to: Ms. Karen Wright, Office of Technology Development, National Eye Institute, Building 10, Room 10N202, Bethesda, MD 20892 (301/496&hyph;9463). CRADA proposals must be received by the date specified below.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Licensing proposals and questions about this opportunity should be addressed to: Ms. Carol Lavrich, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Rockville, MD 20852 (301/496&hyph;7735 ext. 287). Information on the patent and patent applications and pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement. Respondees interested in licensing the invention(s) will be required to submit an Application for License to Public Health Service Inventions. Respondees interested in submitting a CRADA proposal should be aware that it may be necessary to secure a license to the above patent rights in order to commercialize products arising from a CRADA agreement. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </ADDRESS> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  There is no deadline by which license applications must be received. CRADA proposals must be received on or before November 14, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </DATE> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Antiflammins are biologically active synthetic oligopeptides, derived from the sequence similarity between lipo-cortin-1 and uteroglobin, an anti-inflammatory protein. These peptides have antiphospholipase A <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  and immunomodulatory properties. Because of the great therapeutic potential of specific and potent antiflammin drugs that may be developed, scientists in several Institutes at the National Institutes of Health are examining the use of antiflammins in the treatment of a variety of inflammatory processes, including acute anterior ocular inflammation (uveitis), psoriasis, neonatal respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Dr. Chi-Cho Chan and Dr. Scott Whitcup, clinical investigators at the National Eye Institute (NEI), have an IND for the use of antiflammin 2 in acute anterior uveitis, and seven patients have already been enrolled in a clinical trial. To date, no toxicity has been observed in patients treated with this drug. The NEI is interested in developing new topical formulations of antiflammins and the initiation of multi-center randomized clinical trials of antiflammins for the treatment of anterior uveitis, post-operative ocular inflammation, and allergic conjunctivitis.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Dr. John diGiovanna, an investigator in the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is studying the use of antiflammins to treat psoriasis, a hyperproliferative inflammatory skin disease. Dr. diGiovanna would like to continue and expand these studies to include other inflammatory skin diseases such as atopic and contact dermatitis, as well as develop animal and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vitro <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  models to study the effects of antiflammins on skin.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <!-- PJG /STAG --></p>
		</main>
</body></html>
            